The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Open accessAbstract
BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). METHODS: . RESULTS: for superiority). The median duration of follow-up was 15.3 months. After 18 months, the progression-free survival rate was 63.0% (95% confidence interval [CI], 54.6 to 70.3) in the ribociclib group and 42.2% (95% CI, 34.8 to 49.5) in the placebo group. In patients with measurable disease at baseline, the overall response rate was 52.7% and 37.1%, respectively (P<0.001). Common grade 3 or 4 adverse events that were reported in more than 10% of the patients in either group were neutropenia (59.3% in the ribociclib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuation because of adverse events were 7.5% and 2.1%, respectively. CONCLUSIONS: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT01958021 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of exposure to trial treatment in the ribociclib group was 20.2 months (interquartile range, 7.4 to 45.1), which is 7 months longer than it was at the time of the primary analysis of progression-free survival. 10”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the primary and updated analyses of MONALEESA-2, progression-free survival was significantly longer with ribociclib plus letrozole than with placebo plus letrozole (median in updated analysis, 25.3 months vs. 16.0 months; hazard ratio for disease progression or death, 0.57; 95% confidence interval [CI], 0.46 to 0.70; P<0.001).”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data for overall survival were immature at the time of the primary and updated analyses.”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the primary and updated analyses of MONALEESA-2, progression-free survival was significantly longer with ribociclib plus letrozole than with placebo plus letrozole (median in updated analysis, 25.3 months vs. 16.0 months; hazard ratio for disease progression or death, 0.57; 95% confidence interval [CI], 0.46 to 0.70; P<0.001).”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of CDK4/6 inhibitors (ribociclib, abemaciclib, and palbociclib) improved progression-free survival in this patient population, leading to regulatory approvals. 9-13”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
In the citing paper
“However, 10% of the patients treated with abemaciclib develop grade 3 diarrhea, which is very rare with the other two inhibitors (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationMECHANISMS OF ENDOCRINE RESISTANCE IN BREAST CANCER
Osborne, C., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,205
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020299707510 · Cited by 589
Flagged first, then by citations
Research works printed but not linked: 2
- Infante JR, Clin Cancer Res
- Vuppalanchi R, Hepatology
Cited by
Sorted by citations
Items 801–900 of 1,000
Chen, F., Zhang, Z., Yu, Y., Liu, Q., & Pu, F. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5057 · Cited by 17
“Treatment using highly selective CDK4/6 inhibitors, including palbociclib, ribociclib and abemaciclib, have been previously reported to improve progression-free survival (PFS) in the first and later lines of ER+ metastatic breast cancer therapy (13-18).”
Fiste, O., Liontos, M., Koutsoukos, K., Terpos, E., Dimopoulos, M. A., & Zagouri, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1175 · Cited by 16
“are human epidermal growth factor receptor 2 (HER2) inhibitors for the treatment of HER2+ disease; palbociclb (14), ribociclib (15) and abemaciclib (16) are cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors for the treatment of hormone-receptor (HR)+, HER2− disease, in combination with hormonal treatment, like aroma…”
BackgroundHe, F., Zhang, Q., Chen, Y., Ge, S., Xie, Y., Sun, R., Wu, Y., & Xu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5564 · Cited by 18
“In three large randomized phase III trials, the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib were inves‑ tigated when each was combined with AIs in the first‑line treatment of postmenopausal patients with HR + /HER2 ‑ MBC (59,65,69).”
InfluentialCDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer
Wu, Z., Wang, M., Li, F., Wang, F., Jia, J., Feng, Z., Huo, X., Yang, J., Wen, J., Sa, R., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707295 · Cited by 16
“HMGA2 could be considered a novel target gene for the precision therapy due to its vital role in cancer and the specific expression characteristics in different developmental stages (Zhu et al., 2017; Huang et al., 2018).”
BackgroundKim, J., Oh, J. M., Park, Y. H., Ahn, J. S., & Im, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759150 · Cited by 16
Lv, C., Yang, H., Yu, J., & Dai, X. (2022) · Environmental Toxicology · doi:10.1002/tox.23495 · Cited by 16
Sharaf, B., Abu‐Fares, H., Tamimi, F., Al-Sawajneh, S. F., Salama, O., Daoud, R., Alhajahjeh, A. A., Al-lababidi, S., & Abdel‐Razeq, H. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s415432 · Cited by 16
Lee, E. Y., Lee, D., Lee, K.-H., & Im, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.846 · Cited by 18
“…trial showed increased PFS with ribociclib/ letrozole compared to letrozole alone (25.3 vs. 16.0 months; hazard ratio, 0.568; p=9.63×10 –8 ) [13,14], and MONALEE-SA-7 was the first study to demonstrate overall survival (OS) benefits for adding ribociclib to therapy with goserelin and either…”
InfluentialMechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Marra, A., Trapani, D., Ferraro, E., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_9 · Cited by 16
Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors
Zhu, J., Cai, Y., Kong, M., Li, Y., Zhu, L., Zhang, J., Yu, Z., Xu, S.-S., Hong, L., Chen, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01890 · Cited by 16
Lashen, A., Algethami, M., Alqahtani, S., Shoqafi, A., Sheha, A., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074060 · Cited by 16
Neuroendocrine neoplasms of the breast: a review of literature
Vegni, F., Stefano, I. S. D., Policardo, F., Tralongo, P., Feraco, A., Carlino, A., Ferraro, G., Zhang, Q., Scaglione, G., D’Alessandris, N., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03856-y · Cited by 17
Chen, B.-F., Tsai, Y., Chao, T., Lien, P., Lin, Y., Feng, C.-J., Chen, Y.-J., Cheng, H.-F., Liu, C., Lai, J., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01458-1 · Cited by 16
“[1, 20, 21, 25] This discrepancy may be due to the inconvenience of changing the dose within the constraints of NHI reimbursement policies, which leads physicians to interrupt treatment rather than to adjust the dose.”
InfluentialSelf-citationBøttcher, T. M., Cold, S., & Jensen, A. B. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1532603 · Cited by 16
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
Yardley, D. A., Hart, L. L., Favret, A. M., Blau, S. H., Diab, S., Richards, D., Sparano, J. A., Beck, J. T., Richards, P. D., Ward, P. J., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.02.007 · Cited by 16
Self-citationToss, A., Venturelli, M., Sperduti, I., Molinaro, E., Isca, C., Barbieri, E., Piacentini, F., Omarini, C., Cortesi, L., Cascinu, S., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.011 · Cited by 16
Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019
Cárdenas-Sánchez, J., Erazo-Valle-Solís, A. A., Arce-Salinas, C., Bargalló‐Rocha, E., Piña, V. B., Cervantes-Sánchez, M. G., Flores-Balcázar, C. H., Lluch-Hernández, A., Maffuz‐Aziz, A., Pérez-Sánchez, V. M., et al. (2019) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.m19000180 · Cited by 20
Current and emerging biologic therapies for triple negative breast cancer
Shaikh, S. S., & Emens, L. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801627 · Cited by 17
Servetto, A., Napolitano, F., Angelis, C. D., Placido, P. D., Giuliano, M., Arpino, G., Placido, S. D., Bianco, R., & Formisano, L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103191 · Cited by 16
“MONALEESA-2 trial [5], to investigate CNAs of the 8p11.”
BackgroundPapageorgiou, C., Zagouri, F., Tampakis, K., Georgakopoulou, R., Manios, E. D., Kafouris, P. P., Benetos, G., Koutagiar, I. P., Anagnostopoulos, C., Dimopoulos, M. A., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.638895 · Cited by 16
Jeong, E., Wang, C., Wilson, L., & Zhong, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658054 · Cited by 17
“In this pivotal trial, pre/perimenopausal women with advanced or metastatic breast cancer received endocrine therapy (tamoxifen or a non-steroidal aromatase inhibitor (NSAI)) either alone or in combination with ribociclib (9, 13).”
BackgroundAmaro, C. P., Batra, A., & Lupichuk, S. (2021) · Current Oncology · doi:10.3390/curroncol28030209 · Cited by 16
Combined endocrine and targeted therapy in luminal breast cancer
Cesca, M. G., Pandolfi, N. C., Maciel, D., Lima, J., Sanches, S. M., & Ponde, N. F. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1960160 · Cited by 16
“3 trials, the final overall survival reports are still to be published [62,63,68,71,82].”
BackgroundBreast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
Duranti, S., Fabi, A., Filetti, M., Falcone, R., Lombardi, P., Daniele, G., Franceschini, G., Carbognin, L., Palazzo, A., Garganese, G., et al. (2021) · Cancers · doi:10.3390/cancers13205198 · Cited by 16
“In metastatic disease, the CDK4/6 inhibitors associated with endocrine therapy radically changed clinical practice due to a remarkable improvement in terms of PFS compared to hormone therapy alone of 9–13 months in first line [9,10,15,16,24,25], of 8–11 months in both first second line [26–29]), and of 5–7 months in s…”
BackgroundInfluentialLatino, N. J., Galotti, M., Cherny, N. I., de Vries, E. G. E., Douillard, J.-Y., Kaidarova, D., & Ilbawi, A. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100362 · Cited by 16
The CDK4/6 inhibitor in HR-positive advanced breast cancer
Ding, W., Li, Z., Wang, C., Ruan, G., Chen, L., & Tu, C. (2018) · Medicine · doi:10.1097/md.0000000000010746 · Cited by 16
Zheng, Y., Zhong, G., Yu, K., Lei, K., & Yang, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00148 · Cited by 16
Han, Y., Wang, J., Wang, Z., & Xu, B. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100606 · Cited by 16
Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
Lee, Y.-T., Chuang, Y., & Chan, M. W. Y. (2020) · Epigenomes · doi:10.3390/epigenomes4040027 · Cited by 18
da Silva, J. L., Oliveira, L. J. D. C., de Resende, C. A. A., Reinert, T., de Albuquerque, L. Z., Leite, L. F., & Mano, M. S. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251353623 · Cited by 17
“47,48 Variations in pharmacokinetics and FGFR pathway dynamics could also result in differing clinical outcomes, with ribociclib offering more sustained inhibition of cell proliferation in tumors with high FGFR signaling despite possible resistance mechanisms.”
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
Wortelboer, N., van Ommen‐Nijhof, A., Konings, I. R. H. M., van der Noort, V., van den Pol, E., Páez, C. G., Bakker, S. D., Hovenga, S., Imholz, A. L. T., Kamm, Y. J. L., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2025.6585 · Cited by 19
Self-citationTranscription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16
Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer
Schieber, T. J., Steele, S., Collins, S., Berger, M. J., Fleming, M., McLaughlin, E. M., Sudheendra, P. K., & Vargo, C. A. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.009 · Cited by 15
Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer
Gnant, M., Turner, N. C., & Hernándo, C. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390922 · Cited by 17
Agapow, P., Mulla, R., Markuzon, N., Ottesen, L. H., & Meulendijks, D. (2023) · Future Oncology · doi:10.2217/fon-2022-0616 · Cited by 15
Brufsky, A., Kwan, M. L., Sandin, R., Stergiopoulos, S., Karanth, S. S., Cha-Silva, A. S., Makari, D., & Goyal, R. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07469-6 · Cited by 15
Burris, H. A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1435275 · Cited by 15
“dermal growth factor receptor 2-negative (HER2−) advanced breast cancer [14,15], and have been licensed in this setting”
BackgroundInfluentialSelf-citationPiccinni, C. P., Dondi, L., Ronconi, G., Calabria, S., Pedrini, A., Esposito, I., Martini, N., & Marangolo, M. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00822-4 · Cited by 15
Eiger, D., Wagner, M., Ponde, N. F., Nogueira, M. S., Buisseret, L., & de Azambuja, E. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1738547 · Cited by 15
Oswald, L. B., Arredondo, B. L., Kadono, M., Martinez‐Tyson, D., Meade, C. D., Penedo, F. J., Antoni, M. H., Soliman, H. H., Costa, R. L. B., & Jim, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4055 · Cited by 15
Garufi, G., Carbognin, L., Orlandi, A., Palazzo, A., Tortora, G., & Bria, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651723 · Cited by 15
Oswald, A. J., Symeonides, S. N., Wheatley, D. A., Chan, S. Y. T., Brunt, A. M., McAdam, K., Schmid, P., Waters, S. H., Poole, C. J., Twelves, C. J., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06873-8 · Cited by 15
Self-citationHormone receptor positive breast cancer: state of the art
Peddi, P. F. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000424 · Cited by 15
Riccardi, F., Colantuoni, G., Diana, A., Mocerino, C., Carten�, G., Lauria, R., Febbraro, A., Nuzzo, F., Addeo, R., Marano, O., et al. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1672 · Cited by 15
Lee, K. A., Shepherd, S. T. C., & Johnston, S. R. D. (2019) · Future Oncology · doi:10.2217/fon-2019-0169 · Cited by 15
Awada, A. H., Gligorov, J., Jérusalem, G., Preusser, M., Singer, C. F., & Zielinski, C. C. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000565 · Cited by 14
Giuliani, J., & Bonetti, A. V. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220934531 · Cited by 15
Ribociclib plus fulvestrant in the treatment of breast cancer
Neven, P., Sonke, G. S., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840360 · Cited by 15
Self-citationCDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?
Xu, B., & Fan, Y. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30757-9 · Cited by 15
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
Gallego, G. M., Palmer, C. L., Orr, S. T. M., Bernier, L., Chen, P., Cho-Schultz, S., Deal, J. G., Dress, K. R., Edwards, M. P., Jalaie, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02137 · Cited by 14
Fasching, P. A., Schneeweiß, A., Kolberg, H., Ettl, J., Fehm, T. N., Overkamp, F., & Lüftner, D. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000510 · Cited by 14
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
Lanceta, L., Lypova, N., O’Neill, C. H., Li, X., Rouchka, E. C., Chesney, J. A., & Imbert-Fernandez, Y. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06127-5 · Cited by 14
Moloney, C., & Shiely, F. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.03.011 · Cited by 16
Ravish, A., Shivakumar, R., Zhang, X., Yang, M. H., Yang, J.-R., Swamynayaka, A., Nagaraja, O., Mahendra, M., Chinnathambi, A., Alharbi, S. A., et al. (2023) · Bioengineering · doi:10.3390/bioengineering10020159 · Cited by 14
Franco, R. C. D. O., Cao, J. Q., Yassa, M., & Hijal, T. (2023) · Current Oncology · doi:10.3390/curroncol30060415 · Cited by 14
“More recently, the association of these agents with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has demonstrated substantial improvement in progression-free survival [1,2] and overall survival [3,4], additionally supporting the standard use of CDK4/6 inhibitors and antiestrogen therapy combination.”
BackgroundKhorrami, M., Viswanathan, V. S., Reddy, P., Braman, N. M., Kunte, S., Gupta, A. B., Abraham, J., Montero, A. J., & Madabhushi, A. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00574-7 · Cited by 14
Jhaveri, K. L., O’Shaughnessy, J., Fasching, P. A., Tolaney, S. M., Yardley, D. A., Sharma, V. K., Biswas, C., Thuerigen, A., Pathak, P., & Rugo, H. S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231216095 · Cited by 15
“2,4,8,18 Although the inclusion and exclusion criteria for the two trials were generally similar, there were some differences that were reflected in a small subset of patients.”
BackgroundSelf-citationMurad, B., Reis, P. C. A., Marinho, A. D., Comini, A. C. M., Xavier, D. P., Pessoa, B., Raheem, F., Ernst, B. J., Mina, L. A., & Batalini, F. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae078 · Cited by 15
André, F., Solovieff, N., Su, F., Bardia, A., Neven, P., Yap, Y. S., Tripathy, D., Lu, Y., Slamon, D., Chia, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.010 · Cited by 18
Self-citationPilehvari, A., Kimmick, G. G., You, W., Bonilla, G., & Anderson, R. T. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01902-w · Cited by 14
“Following the PALOMA trials, the MONALEESA trials examined Ribociclib [15–17], and later, the MONARCH trials studied Abemaciclib [18, 19].”
MethodInfluentialVernieri, C., Milano, M., Mennitto, A., Maggi, C., Ferrari, B., Rinaldi, L., Mennitto, R., Stefanetti, C., Re, B., Mariani, G., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4336-z · Cited by 14
Targeted therapy for breast cancer in older patients
Ponde, N. F., Wildiers, H. P. M. W., Awada, A. H., de Azambuja, E., Deliens, C., & Lago, L. D. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.012 · Cited by 14
Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Kietzman, W. B., Graham, G. T., Ory, V., Sharif, G. M., Kushner, M. H., Gallanis, G. T., Kallakury, B., Wellstein, A., & Riegel, A. T. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0231 · Cited by 14
Arrhythmogenic Anticancer Drugs in Cardio-Oncology
Rhea, I. B., Burgos, P. H., & Fradley, M. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.011 · Cited by 14
Hachem, G. E., Gombos, A., & Awada, A. H. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1834385 · Cited by 15
Manso, L., Hernándo, C., Galán, M., Oliveira, M., Cabrera, M. A., Bratos, R., Rodriguez, C. A., Ruíz‐Borrego, M., Blanch, S., Llombart‐Cussac, A., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.11.005 · Cited by 14
“Palbociclib, together with the others CDK4/6 inhibitors ribociclib and abemaciclib, received FDA and EMA approval for the treatment of HRþ/HER2- mBC in combination with either AIs or fulvestrant based on the PALOMA-2, MONALEESA 2 and the MONARCH 2 randomized clinical trials, respectively [12,15,17,18].”
MethodYuan, Y., Zhang, S., Yan, M., Yin, Y., Song, Y., & Jiang, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8252 · Cited by 14
“In the past decade, randomized controlled trials (RCTs) (9-14) have led to introducing several innovative therapeutic strategies into clinical practice, consisting of single-agent ET and new targeted drugs combined with ET.”
BackgroundAnti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, M., & Smyth, E. C. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.3 · Cited by 14
Wong, V., BOER, R. D., Baron-Hay, S. E., Blum, R., Boyle, F. M., Chua, S. L. L., Clarke, K., Cuff, K. E., Green, M., Lim, E., et al. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.08.011 · Cited by 16
The safety and efficacy of palbociclib in the treatment of metastatic breast cancer
Ettl, J., & Harbeck, N. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1347506 · Cited by 14
“With positive phase III data already published [29], ribociclib has recently been approved in the US and the EU approval is expected for the second half of 2017.”
BackgroundSabatier, R., Dieras, V. C., Pivot, X. B., Brain, E. G. C., Roche, H. H., Extra, J.-M., Monneur, A., Provansal, M., Tarpin, C., Bertucci, F., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.446 · Cited by 14
Goldschmidt, D., Dalal, A. A., Romdhani, H., Kelkar, S. S., Guérin, A., Gauthier, G., Wu, E. Q., Niravath, P. A., & Small, T. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0676-2 · Cited by 15
Ayyagari, R., Tang, D. H., Patterson‐Lomba, O., Zhou, Z., Xie, J., Chandiwana, D., Dalal, A. A., & Niravath, P. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1479246 · Cited by 14
Haruta, M., Arai, Y., Okita, H., Tanaka, Y., Takimoto, T., Sugino, R. P., Yamada, Y., Kamijo, T., Oue, T., Fukuzawa, M., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.007 · Cited by 14
BISKUPIAK, J. E., Oderda, G. M., Brixner, D. I., Tang, D. H., Zacker, C., & Dalal, A. A. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.8.859 · Cited by 14
Alpelisib in the Treatment of Metastatic HR+ Breast Cancer with PIK3CA Mutations
Mavratzas, A., & Marmé, F. (2020) · Future Oncology · doi:10.2217/fon-2020-0464 · Cited by 15
Mavratzas, A., & Marmé, F. (2021) · Breast Care · doi:10.1159/000514561 · Cited by 14
Ateş‐Alagöz, Z., Kışla, M. M., Karadayı, F. Z., Baran, S., Doğan, T. S., & Mutlu, P. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02808a · Cited by 14
Hinged total knee replacement: indications and results.
Cameron, H. U., & Jung, Y. B. (1990) · PubMed · Cited by 14
Hart, L. L., Im, S., Tolaney, S. M., Campone, M., Pluard, T., Sousa, B., Freyer, G., Decker, T., Kalinsky, K. M., Sopher, G. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115225 · Cited by 15
Self-citationTargeting CDK2 and other novel cell cycle targets for breast cancer therapy
Chen, M., Luo, L., Massoumi, N. L., & Keyomarsi, K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2537412 · Cited by 14
U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer
Nunes, A. P., Liang, C., Gradishar, W. J., Dalvi, T. B., Lewis, J., Jones, N., Green, E., Doherty, M., & Seeger, J. D. (2019) · Current Oncology · doi:10.3747/co.26.4163 · Cited by 13
Hepatotoxicity of FDA-approved small molecule kinase inhibitors
Jiang, H., Jin, Y., Yan, H., Xu, Z., Yang, B., He, Q., & Luo, P. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1867104 · Cited by 13
“All four cases did not result in death and returned to normal after discontinuation of ribociclib [21].”
BackgroundCicini, M. P., Ferretti, G., Morace, N., Nisticò, C., Cognetti, F., & Rulli, F. (2021) · Breast Care · doi:10.1159/000519728 · Cited by 13
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Yang, L., Chen, Y., Wang, N., & Han, W. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-36 · Cited by 14
Guan, Y., Shen, G., Fang, Q., Xin, Y., Huo, X., Li, J., Zhao, F., Ren, D., Liu, Z., Li, Z., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00814-3 · Cited by 13
Sanò, M. V., Martorana, F., Lavenia, G., Rossello, R., Prestifilippo, A., Sava, S., Ricciardi, G. R. R., & Vigneri, P. G. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2052277 · Cited by 13
“was the primary endpoint, while secondary end-points including, among others, OS, and objective response rates (ORR) [17].”
BackgroundInfluentialSathe, C. M., Accordino, M. K., DeStephano, D. M., Shah, M., Wright, J. D., & Hershman, D. L. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06957-5 · Cited by 13
“It was similarly exceedingly low in large Phase 3 trials of ribociclib [13] and abemaciclib [7].”
BackgroundJi, Y., Darstein, C., Yang, S., Quinlan, M., Chakravartty, A., Zarate, J. P., Chakraborty, A., & Ho, Y. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2310 · Cited by 14
Ji, D., Luo, Y., Wang, J., Chen, S., Lan, B., Ma, F., Xu, B., & Fan, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11290-7 · Cited by 13
Avcı, O., İriağaç, Y., Çavdar, E., Karaboyun, K., Araz, M., Şakalar, T., Değerli, E., Özdemir, Ö., İnal, A., Ocak, B., et al. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101604 · Cited by 13
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
Quan, C., Wu, Z., Xiong, J., Li, M., Fu, Y., Su, J., Wang, Y., Ning, L., Zhang, D., & Xie, N. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00462-7 · Cited by 14
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
Ke, S., Dang, F., Wang, L., Chen, J.-Y., Naik, M. T., Li, W., Thavamani, A., Kim, N., Naik, N. M., Sui, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47427-w · Cited by 15
Lashen, A., Alqahtani, S., Shoqafi, A., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095053 · Cited by 13
Li, J., Zhao, B., Zhu, Y.-Q., & Wu, J. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/5132916 · Cited by 13
Ding, H., Xu, W., Dai, M., Li, S., Xin, W., Tong, Y., He, C., Mi, X., Zhan, Z., & Fang, L. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2348566 · Cited by 13
“These hematological AEs often necessitate dose reduction or discontinuation of CDK4/6 inhibitors, potentially compromising patient survival [9,12,13].”
Wu, D., Pan, C., Hu, Y., Shi, Z., Zhou, Y., & Xiao, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366900 · Cited by 13
Hong, R., Xu, F., Xia, W., Teng, Y., Ouyang, Q., Zheng, Q., Yuan, Z., Chen, D., Jiang, K., Lin, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.00938 · Cited by 15
Fasching, P. A., Slamon, D. J., Nowecki, Z. I., Kukiełka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C., Chan, A., Chia, S., Martín, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1724 · Cited by 15
Self-citationCombination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
Olson, E. A. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.1.3 · Cited by 13
“, 2016) and MONALEESA-2 (Hortobagyi et al., 2016) studies were published, showing strong evidence for improved outcomes in postmenopausal women who had not received prior treatment for advanced disease when a CDK4/6 inhibitor is added to letrozole (Finn et al.”
BackgroundMethodInfluential
Metadata
- Authors
- Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan, A., Jakobsen, E., Nusch, A., Burdaeva, O., Grischke, E.-M., Alba, E., Wist, E., Marschner, N., Favret, A. M., Yardley, D., Bachelot, T., Tseng, L.-M., Blau, S., Xuan, F., Souami, F., Miller, M., Germa, C., Hirawat, S., & O’Shaughnessy, J.
- Affiliations
- From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology–Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) — all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) — both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt–Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) — all in Nashville; National Cancer Center...
- The University of Texas MD Anderson Cancer Center (US)
- Université Paris-Sud (FR)
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Stemmer, Salomon M.
- Burris, Howard A.
- Yap, Yoon-Sim
- Sonke, Gabe S.
- Campone, Mario
- Blackwell, Kimberly L.
- André, Fabrice
- Winer, Eric P.
- Janni, Wolfgang
- Verma, Sunil
- Conte, Pierfranco
- Arteaga, Carlos L.
- Cameron, David A.
- Chan, Arlene
- Jakobsen, Erik
- Grischke, Eva-Maria
- Alba, Emilio
- Wist, Erik
- Marschner, Norbert
- Favret, Anne M.
- Yardley, Denise
- Bachelot, Thomas
- Tseng, Ling-Ming
- Blau, Sibel
- Xuan, Fengjuan
- Miller, Michelle
- Germa, Caroline
- O’Shaughnessy, Joyce
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-03
- Volume
- 375
- Issue
- 18
- Pages
- 1738-1748
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528767298
- Cited by
- 2,039
- References
- 24
- Citations by year
- 2026: 167 · 2025: 218 · 2024: 203 · 2023: 214 · 2022: 187 · 2021: 247 · 2020: 206 · 2019: 173 · 2018: 237 · 2017: 166 · 2016: 17
- FWCI
- 176.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Spectrum Pharmaceuticals
- Celgene
- Exelixis
- Celldex Therapeutics
- TG Therapeutics
- Astex Pharmaceuticals
- Agios Pharmaceuticals
- Jounce Therapeutics
- Mersana Therapeutics
- Incyte
- G1 Therapeutics
- Eisai
- Astellas Pharma
- Ipsen
- Genentech
- Chugai Pharmaceutical
- Novartis Institutes for BioMedical Research
- Loxo Oncology
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, hormone receptor-positive HER2-negative breast cancer, advanced breast cancer, first-line therapy, letrozole, endocrine therapy resistance, progression-free survival, myelosuppression, neutropenia, leukopenia
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Staging, Nitriles, Purines, Receptors, Estrogen, Receptors, Progesterone, Triazoles, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
